Eli Lilly's disclosure of 62% LDL-C reduction with high-dose VERVE-102 represents the first human in-vivo CRISPR base editing data targeting PCSK9 for cholesterol lowering, yet the STAT report underplays critical limitations of this non-peer-reviewed Phase 1 announcement. Unlike large-scale RCTs underpinning statins (e.g., 4S trial, n>4,000, 30-year follow-up showing mortality benefit), this open-label study enrolled a small cohort with undisclosed sample size per dose, short follow-up, and no randomization—typical of early safety trials prone to selection bias and placebo effects. Prior Verve candidate VERVE-101 was halted over liver enzyme elevations, making the absence of serious adverse events here noteworthy but insufficient without independent verification of off-target editing or long-term durability. Lilly's $1B acquisition introduces clear conflicts of interest, as corporate incentives favor positive framing over the observational data patterns seen in prior gene therapies where initial enthusiasm waned post-approval. Synthesizing with Musunuru et al. (Nature Medicine, 2021, n=10 non-human primates) and the 2023 VERVE-101 interim report (small human cohort), this platform could bypass daily statin adherence barriers affecting 50% of patients, yet equity concerns around one-time $500k+ pricing and access in low-resource settings remain unaddressed. Deeper analysis reveals missed connections to broader cardiovascular prevention: base editing offers potential one-and-done intervention superior to PCSK9 monoclonal antibodies in persistence, but without head-to-head data or Mendelian randomization insights on lifelong PCSK9 loss, overstatement risks repeating inclisiran rollout pitfalls.